Serpil ERDOĞAN, Gönül ERDEN, Birsen SAHİLLİOĞLU, Mustafa Metin YILDIRIMKAYA

Türk erkeklerinde prostat kanseri tanısında serbest/total prostat spesifik antijen oranının tanısal yeterlilik bakımından değerlendirilmesi ve uygun cut off değerinin araştırılması

Amaç: Serum total prostat spesifk antijen (PSA) değeri 4-10 ng/mL arasında bulunanhastalarda, prostat kanseri (PCa) ve benign prostat hipertrofsi (BPH) ayrımında, serbest/ total PSA oranının tek başına total PSA kullanımından daha faydalı olduğu bildirilmektedir.Ancak bildirilmiş cut off değerleri arasında farklar bulunabilmektedir. Bu çalışmada labo- ratuvara başvuran hastalar için serum serbest/total PSA oranı cut off değeri tayini amaç- lanmıştır. Yöntem: Bu çalışmada, yaşları 56-84 arasında değişen (ortalama±S.D.; 68.1±6.8), totalPSA değerleri 4-10 ng/mL arasında bulunan, TRUS+PBx (transrektal ultrasonograf eşliğindesistematik prostat biyopsisi) ile elde edilen patolojik tanılarına göre ayrımı yapılan, 31 BPHve 20 PCa’lı hastada serum total ve serbest PSA düzeyleri kemilüminesans mikropartikülimmunokimyasal (CMIA) yöntem (Architect i2000, Abbott) ile tayin edilmiştir. Bu parametre- lerin ve serbest/total PSA oranının duyarlılık, özgüllük, pozitif ve negatif kestirim değerleri,ROC (receiver operating characteristic-nispi işlemleme özelliği) analizleri ve aralarındakiuyumluluk çalışmaları yapılmıştır. Bulgular: Serum serbest/total PSA oranı ortalama değeri, PCa’lı olgularda 0.19 (0.01- 0.60) iken, BPH grubunda 0.25 (0.10-0.48) bulunmuştur (p

Evaluation of the diagnostic value of free/total prostate specifc antigen for prostat cancer in Turkish males, investigating the appropriate cut off value

Objective: It is reported that using only free-to-total PSA ratio in differential diagnosisbetween prostate cancer and benign prostatic hyperplasia (BPH) in the patients with 4-10ng/mL PSA values is more useful than total PSA. However, different cut-off values have beenreported. In this study, it was aimed to determine cut-off value of the free PSA to total PSAin the serum of the patients who applied to the laboratory.Method: In this study, a total of 51 patients who had PSA values between 4-10 ng/mLand age between 56-84 years old (mean: 68.1±6.8) were included. Sera were obtained frompathologically diagnosed with TRUS+PBx (transrectal ultrasonographic sistematic prostatebiopsy) 31 BPH and 20 PCa patients. Serum total and free PSA values were determined withchemiluminescent microparticle immunoassay (CMIA) (Architect i2000, Abbott). Sensitivity,specifcity, positive predictive value, negative predictive value were calculated; receiveroperating characteristic (ROC) analyses and the correlation between them were determi- ned. Results: While average serum free/total PSA ratio was 0.19 (0.01-0.60) in the prostatecancer group, it was found0.25 (0.01-0.48) in the BPH group (p

PDF

___

Timothy R. Church. Prostate-Specif c Antigen and Prostate Cancer Prognosis. Journal of the National Cancer Institute 2006; 98:1509-10.
Oesterling JE. Prostate specifc antigen: a critical assessment of the most useful tumor marker for adeno- carcinoma of the prostate. J Urol 1991;145:907-23.
Yavuz T, Diler A, Gül G, Fatma ZK. Tıbbi Laboratuvarlarda Standardizasyon ve Kalite Yönetimi. İstanbul. Mert Matbaacılık Hizmetleri, 2000; 255-64.
Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specifc antigen as prescreening test for prostate cancer. J Urol 1992;147:846-51.
Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specifc antigen density to enhance the predictive value of intermediate levels of serum prostate specifc antigen. J Urol 1992; 147:817-21.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specifc antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
Oesterling JE, Jacobsen SJ, Chutte CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate specifc antigen in a community-based population of healthy man. Establishment of age-spesifc reference ranges. JAMA 1993;270:860-4.
Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjus ted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of prostate. Urology 1994;43:601-6.
Catalona WJ, Smith DS, Wolfer RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specifc antigen to improve specifty of prostate cancer screening. JAMA 1995;274:1214-20.
Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specifc antigen density of transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997;157:1315-21.
Oesterling JE. Prostate specifc antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907-23.
Dalva I, Akan H, Yildiz O, Telli C, Bingol N. The clinical value of the ratio of free prostate specifc antigen to total prostate specifc antigen. Int Urol Nephrol. 1999;31(5):675-80.
Lilja H, Cockett AT, Abrahamsson PA. Prostate specifc antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specifc antigen in serum. Cancer. 1992 Jul 1;70(1 Suppl):230-4.
Cookson MS, Floyd MK, Ball TP Jr, Miller EK, Sarosdy MF. The lack of predictive value of prostate specifc antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specifc antigen levels. J Urol 1995;154:1070-3.
Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152:1737-40.
Stenman UH, Rannikko S, Alfftan, Tuhkanen O. A complex between prostate-specifc antigen and alpha- 1-antichymotrypsin is the major form of prostatespecifc antigen in serum of patients with prostatic cancer: Assay of the complex improves sensitivity for cancer. Cancer Res 1991;51:222-6.
Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specifc antigen and its complex with a-1antichymotrypsin before diagnosis of prostatic cancer. Lancet 1994;344:1594-8.
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of percentage of free prostatespecifc antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter trial. JAMA 1998;279:1542-7.
Jung K, Meyer A, Lein M, Rudolph B, Schnorr D. and Loening SA. Ratio of free to-total prostate specifc antigen in serum can not distinguish patients with prostate cancer from those chronic infammation of the prostate.J Urol 1998;159:1595-8.
Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/ml. Urology 2003;61:760-4.